Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03111810|
Recruitment Status : Recruiting
First Posted : April 13, 2017
Last Update Posted : March 24, 2020
Currently, 2-3% of the population of the United Kingdom and United States of America receive glucocorticoid therapy. Significant adverse effects are not confined to chronic use; recurrent short-course administration is associated with increased morbidity and mortality. The adverse metabolic features associated with glucocorticoid use include obesity, skeletal muscle myopathy, hypertension, insulin resistance and diabetes and are collectively termed 'iatrogenic Cushing's syndrome'. The efficacy of glucocorticoid therapy is not in doubt, but there are no interventions to reduce their metabolic consequences. Within metabolic tissues (liver, skeletal muscle, adipose), 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) regenerates active glucocorticoid and therefore is able to tightly control the availability of glucocorticoids to activate the glucocorticoid receptor. In preclinical studies, the investigators have shown that 11β-HSD1 is critical in regulating the development of the adverse features associated with circulating glucocorticoid excess, endorsing our observations in a patient with Cushing's disease, who was protected from a classical phenotype due to a functional deficit in 11β-HSD1.
This study is the first clinical evaluation of the impact of the selective 11β-HSD1 inhibitor, AZD4017, in healthy volunteers taking exogenous glucocorticoids (prednisolone). The investigators propose that in tissues expressing high levels of 11β-HSD1, prednisolone action will be amplified, driving adverse effects within these tissues and have hypothesized that AZD4017 in humans will reduce the adverse metabolic consequences of Prednisolone administration without compromise to its anti-inflammatory action.
Our specific research objectives are:
- To demonstrate the beneficial effect of the selective 11β-HSD1 inhibitor, AZD4017, upon the prednisolone-induced deterioration in metabolic phenotype, including glucose disposal and endogenous glucose production rates.
- To determine the impact of AZD4017 on the anti-inflammatory actions of Prednisolone.
- To identify the tissue-specific (skeletal muscle, adipose) mechanisms underpinning the response to Prednisolone therapy administered in conjunction with AZD4017.
The investigators will perform a randomized, double-blind placebo controlled study to determine if co-administration of the selective 11β-HSD1 inhibitor, AZD4017, limits the adverse effects of short-course exogenous glucocorticoid administration. 32 healthy male volunteers will have detailed metabolic investigations including 2-step hyperinsulinaemic euglycaemic clamps (with stable isotope measurements of lipid and carbohydrate metabolism), as well as assessment of skeletal muscle forearm glucose uptake. All volunteers will then be treated with Prednisolone (20mg daily) and randomized to the co-administration of placebo or AZD4017. After 1 week of therapy, all investigations will be repeated. Our hypothesis is that the adverse metabolic effects of Prednisolone will be reduced by co-administration of AZD4017.
|Condition or disease||Intervention/treatment||Phase|
|Iatrogenic Cushing's Disease||Drug: AZD4017 and prednisolone Drug: Placebo Oral Tablet and prednisolone||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||32 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI)|
|Actual Study Start Date :||May 25, 2017|
|Estimated Primary Completion Date :||August 2020|
|Estimated Study Completion Date :||August 2020|
Active Comparator: Active
Prednisolone 20mg once daily and AZD4017 400mg twice daily for 7 days.
Drug: AZD4017 and prednisolone
The drug AZD4017 will be given together with prednisolone 20mg daily for 7 days to compare its effects on metabolic tissues against the placebo arm where the participants will take placebo and prednisolone 20mg daily for 7 days.
Other Name: 11 beta-Hydroxysteroid dehydrogenase inhibitor
Placebo Comparator: Placebo Oral Tablet
Prednisolone 20mg once daily and placebo twice daily for 7 days.
Drug: Placebo Oral Tablet and prednisolone
Placebo Oral tablet will be given together with prednisolone 20mg daily for 7 days to compare the effects on metabolic tissues of AZD4017 and prednisolone 20mg daily against the placebo arm.
Other Name: Placebo
- Changes in the detrimental side effects of prednisolone by AZD4017. [ Time Frame: 2 years ]To evaluate whether AZD4017 can limit the detrimental effect of prednisolone (20mg) on glucose disposal. This will be achieved by measuring glucose disposal during a hyperinsulinaemic euglycaemic clamp.
- Changes in hepatic insulin sensitivity by AZD4017 when given with prednisolone (20mg) compared to prednisolone (20mg) given alone. [ Time Frame: 2 years ]Measurement of endogenous glucose production rate during a hyperinsulinaemic euglycaemic clamp.
- Changes in blood pressure associated with prednisolone and AZD4017 administration [ Time Frame: 2 years ]The participants will have 24h ambulatory blood pressure measurements taken.
- Changes in adipose tissue gene expression profile associated with prednisolone and AZD4017 administration. [ Time Frame: 2 years ]Gene expression changes will be measured from adipose tissue biopsies.
- Change in whole body oxidation associated with prednisolone and AZD4017 administration [ Time Frame: 2 years ]Measurement of incorporation of carbon-13 into breath carbon dioxide using Gas chromatography combustion isotope ratio mass spectrometry.
- Changes in skeletal muscle gene expression profile associated with prednisolone and AZD4017 administration. [ Time Frame: 2 years ]Gene expression changes measured in skeletal muscle biopsies.
- Changes in circulating inflammatory cytokines and inflammatory response in circulating inflammatory cells associated with prednisolone and AZD4017 administration. [ Time Frame: 2 years ]Measurement of inflammatory cytokines, isolation of peripheral blood mononuclear cells and defining their response to inflammatory stress.
- Changes in bone turnover associated with prednisolone and AZD4017 administration. [ Time Frame: 2 years ]Measurement of serum and urine markers of bone turnover including type I collagen cross-linked N-telopeptide and osteocalcin
- Changes in body composition (total and regional lean and fat mass) associated with prednisolone and AZD4017 administration. [ Time Frame: 2 years ]Measurement of total and regional lean and fat mass on dual energy x-ray absorptiometry scan.
- Changes in urinary steroid metabolite profile associated with prednisolone and AZD4017 administration. [ Time Frame: 2 years ]Steroid metabolites measured by gas chromatography, mass spectrometry in a timed overnight urine sample.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03111810
|Contact: Jeremy W Tomlinson, MD PhD||44(0)1865 firstname.lastname@example.org|
|Contact: Nadia Othonos, MB ChB||44(0)1865 email@example.com|